CoChat

Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria

Baird, J. Kevin, Louisa, Melva, Noviyanti, Rintis, Ekawati, Lenny, Elyazar, Iqbal, Subekti, Decy, Chand, Krisin, Gayatri, Anggi, Instiaty, Soebianto, Saraswati, Crenna-Darusallam, Chelzie, Djoko, Dwi, Hasto, Bambang Dwi, Meriyenes, Dubel, Wesche, David, Nelwan, Erni J., Sutanto, Inge, Sudoyo, Herawati, Setiabudy, Rianto · 2018 · JAMA Network Open
Cited by 94

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2018.1449

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 31

  1. Howes, 2016, Global epidemiology of Plasmodium vivax., Am J Trop Med Hyg, 95, 15, 10.4269/ajtmh.16-0141 · DOI · Paper page
  2. Anstey, 2012, Plasmodium vivax: clinical spectrum, risk factors and pathogenesis., Adv Parasitol, 80, 151, 10.1016/B978-0-12-397900-1.00003-7 · DOI · Paper page
  3. Adekunle, 2015, Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo., PLoS Negl Trop Dis, 9, e0003595, 10.1371/journal.pntd.0003595 · DOI · Paper page
  4. Robinson, 2015, Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model., PLoS Med, 12, e1001891, 10.1371/journal.pmed.1001891 · DOI · Paper page
  5. Baird, 2016, Diagnosis and treatment of Plasmodium vivax malaria., Am J Trop Med Hyg, 95, 35, 10.4269/ajtmh.16-0171 · DOI
  6. Howes, 2012, G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map., PLoS Med, 9, e1001339, 10.1371/journal.pmed.1001339 · DOI · Paper page
  7. Price, 2014, Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis., Lancet Infect Dis, 14, 982, 10.1016/S1473-3099(14)70855-2 · DOI · Paper page
  8. Marcsisin, 2016, Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: current state of the art., Pharmacol Ther, 161, 1, 10.1016/j.pharmthera.2016.03.011 · DOI · Paper page
  9. Avula, 2013, Profiling primaquine metabolites in primary human hepatocytes using UHPLC-QTOF-MS with 13C stable isotope labeling., J Mass Spectrom, 48, 276, 10.1002/jms.3122 · doi:10.1002/jms.3122
  10. Pybus, 2013, The metabolism of primaquine to its active metabolite is dependent on CYP 2D6., Malar J, 12, 212, 10.1186/1475-2875-12-212 · DOI · Paper page
  11. Hicks, 2014, Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization., Curr Drug Metab, 15, 218, 10.2174/1389200215666140202215316 · doi:10.2174/1389200215666140202215316
  12. Zhou, 2009, Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I., Clin Pharmacokinet, 48, 689, 10.2165/11318030-000000000-00000 · DOI · Paper page
  13. Zanger, 2004, Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry., Naunyn Schmiedebergs Arch Pharmacol, 369, 23, 10.1007/s00210-003-0832-2 · DOI · Paper page
  14. Bennett, 2013, Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria., N Engl J Med, 369, 1381, 10.1056/NEJMc1301936 · DOI · Paper page
  15. Ingram, 2014, The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea., Malar J, 13, 488, 10.1186/1475-2875-13-488 · DOI
  16. Sutanto, 2013, Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia., Antimicrob Agents Chemother, 57, 1128, 10.1128/AAC.01879-12 · DOI
  17. Nelwan, 2015, Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia., BMC Med, 13, 294, 10.1186/s12916-015-0535-9 · DOI
  18. Gaedigk, 2008, The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype., Clin Pharmacol Ther, 83, 234, 10.1038/sj.clpt.6100406 · DOI · Paper page
  19. Wojtczak, 2007, CYP2D6 phenotyping with dextromethorphan., Pharmacol Rep, 59, 734
  20. Ito, 2010, Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature., Drug Metab Pharmacokinet, 25, 243, 10.2133/dmpk.25.243 · DOI · Paper page
  21. Abduljalil, 2010, Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan., Clin Pharmacol Ther, 88, 643, 10.1038/clpt.2010.137 · DOI
  22. Ward, 1984, Determination of primaquine in biological fluids by reversed-phase high performance liquid chromatography., J Chromatogr A, 305, 239, 10.1016/S0378-4347(00)83337-X · doi:10.1016/s0378-4347(00)83337-x
  23. Mould, 2013, Basic concepts in population modeling, simulation, and model-based drug development—part 2: introduction to pharmacokinetic modeling methods., CPT Pharmacometrics Syst Pharmacol, 2, e38, 10.1038/psp.2013.14 · DOI · Paper page
  24. Keizer, 2013, Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose., CPT Pharmacometrics Syst Pharmacol, 2, e50, 10.1038/psp.2013.24 · DOI · Paper page
  25. Lam, 1993, High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection., Ther Drug Monit, 15, 300, 10.1097/00007691-199308000-00007 · DOI
  26. Daali, 2008, Development and validation of a chemical hydrolysis method for dextromethorphan and dextrorphan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients., J Chromatogr B Analyt Technol Biomed Life Sci, 861, 56, 10.1016/j.jchromb.2007.11.019 · doi:10.1016/j.jchromb.2007.11.019
  27. Sistonen, 2007, CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure., Pharmacogenet Genomics, 17, 93, 10.1097/01.fpc.0000239974.69464.f2 · DOI · Paper page
  28. Baird, 2003, Primaquine for prevention of malaria in travelers., Clin Infect Dis, 37, 1659, 10.1086/379714 · DOI
  29. Baird, 2018, Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms., Malar J, 17, 42, 10.1186/s12936-018-2190-z · DOI
  30. Kitchen, 1949, Malariology: A Comprehensive Survey of All Aspects of This Group of Diseases From a Global Standpoint, 1037
  31. World Health Organization, 2015, Control and Elimination of Plasmodium vivax: A Technical Brief

Cited by

See all 94

Metadata

Authors
Baird, J. K., Louisa, M., Noviyanti, R., Ekawati, L., Elyazar, I., Subekti, D., Chand, K., Gayatri, A., Instiaty, Soebianto, S., Crenna-Darusallam, C., Djoko, D., Hasto, B. D., Meriyenes, D., Wesche, D., Nelwan, E. J., Sutanto, I., Sudoyo, H., & Setiabudy, R.
Affiliations
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Department of Pharmacology, Faculty of Medicine Universitas Indonesia, Jalan Salemba Raya No. 6, Central Jakarta, Indonesia
  • Eijkman Institute of Molecular Biology, Central Jakarta, Indonesia
  • Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology, Central Jakarta, Indonesia
  • Army Health Command, East Jakarta, Indonesia
  • Certara Strategic Consulting, Princeton, New Jersey
  • Division of Tropical Infectious Diseases, Faculty of Medicine, Universitas Indonesia, Central Jakarta, Indonesia
  • Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Central Jakarta, Indonesia
Venue
JAMA Network Open
Published
2018-08-31
Volume
1
Issue
4
Pages
e181449
ISSN
2574-3805
Cited by
94
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.